Arcus Biosciences Inc (RCUS) Implied Volatility Current

Tracking RCUS implied volatility helps you identify when options premiums on Arcus Biosciences Inc are historically cheap or expensive, and where the best trades are hiding. Arcus Biosciences Inc implied volatility reflects the market's expectation of future price movement: when RCUS IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Arcus Biosciences Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For RCUS, tracking metrics like RCUS IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on RCUS signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease.

It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where RCUS implied volatility sits today versus where it has been. Our scanner ranks Arcus Biosciences Inc implied volatility against its historical range, surfaces extremes in RCUS IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Arcus Biosciences Inc IV is rich or cheap — measure it, then act on it.